Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
346 questions in 59 reviews · Vascular
current versionsNo studies 346 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Prostanoids vs pentoxifylline Quality of life · people with critical limb ischaemia Prostanoids for critical limb ischaemia (2018) · Cochrane | no estimate extracted | NR | No studies |
Prostanoids vs lumbar sympathectomy Intermittent and absolute claudication distances · people with critical limb ischaemia due to non‐reconstructable peripheral arterial disease Lumbar sympathectomy versus prostanoids for critical limb ischaemia due to non‐reconstructable peripheral… (2018) · Cochrane | no estimate extracted | NR | No studies |
Prostanoids vs lumbar sympathectomy Quality of life and functional status · people with critical limb ischaemia due to non‐reconstructable peripheral arterial disease Lumbar sympathectomy versus prostanoids for critical limb ischaemia due to non‐reconstructable peripheral… (2018) · Cochrane | no estimate extracted | NR | No studies |
Endovascular revascularisation plus conservative therapy vs conservative therapy alone Pain‐free walking distance (long‐term) · intermittent claudication Endovascular revascularisation versus conservative management for intermittent claudication (2018) · Cochrane | no estimate extracted | NR | No studies |
Endovascular revascularisation vs no specific therapy Quality of life (disease‐specific) · intermittent claudication Endovascular revascularisation versus conservative management for intermittent claudication (2018) · Cochrane | no estimate extracted | NR | No studies |
High cell dose vs low cell dose Wound ulcer healing · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | no estimate extracted | NR | No studies |
High cell dose vs low cell dose Reduction in rest pain · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | no estimate extracted | NR | No studies |
High cell dose vs low cell dose Improvement in lower limb perfusion: ABI · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | no estimate extracted | NR | No studies |
High cell dose vs low cell dose Improvement in lower limb perfusion: TcO₂ · people with critical lower limb ischaemia Autologous cells derived from different sources and administered using different regimens for 'no‐option'… (2018) · Cochrane | no estimate extracted | NR | No studies |
ASA vs placebo Mortality · people with antiphospholipid antibodies and no history of thrombosis Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with… (2018) · Cochrane | no estimate extracted | NR | No studies |
ASA vs placebo Quality of life · people with antiphospholipid antibodies and no history of thrombosis Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with… (2018) · Cochrane | no estimate extracted | NR | No studies |
ASA with LMWH vs placebo or IVIG Mortality · people with antiphospholipid antibodies and no history of thrombosis Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with… (2018) · Cochrane | no estimate extracted | NR | No studies |
ASA with LMWH vs placebo or IVIG Quality of life · people with antiphospholipid antibodies and no history of thrombosis Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with… (2018) · Cochrane | no estimate extracted | NR | No studies |
ASA + high‐dose LMWH vs ASA + low‐dose LMWH or UFH Mortality · people with antiphospholipid antibodies and no history of thrombosis Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with… (2018) · Cochrane | no estimate extracted | NR | No studies |
ASA + high‐dose LMWH vs ASA + low‐dose LMWH or UFH Quality of life · people with antiphospholipid antibodies and no history of thrombosis Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with… (2018) · Cochrane | no estimate extracted | NR | No studies |
Anticoagulant with or without ASA vs ASA only Mortality · people with antiphospholipid antibodies and no history of thrombosis Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with… (2018) · Cochrane | no estimate extracted | NR | No studies |
Anticoagulant with or without ASA vs ASA only Quality of life · people with antiphospholipid antibodies and no history of thrombosis Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with… (2018) · Cochrane | no estimate extracted | NR | No studies |
Stem cell therapy (any source) vs any other modality of treatment Rate of amputation · individuals with thromboangiitis obliterans (Buerger's disease) Stem cell therapy for treatment of thromboangiitis obliterans (Buerger's disease) (2018) · Cochrane | no estimate extracted | NR | No studies |
Stem cell therapy (any source) vs any other modality of treatment Pain Measured using a validated pain score or scale, or quality of life questionnaire · individuals with thromboangiitis obliterans (Buerger's disease) Stem cell therapy for treatment of thromboangiitis obliterans (Buerger's disease) (2018) · Cochrane | no estimate extracted | NR | No studies |
Stem cell therapy (any source) vs any other modality of treatment Adverse effects Local or systemic inflammatory response, cardiovascular abnormalities, and thromboembolic complications · individuals with thromboangiitis obliterans (Buerger's disease) Stem cell therapy for treatment of thromboangiitis obliterans (Buerger's disease) (2018) · Cochrane | no estimate extracted | NR | No studies |
Stem cell therapy (any source) vs any other modality of treatment Amputation‐free survival · individuals with thromboangiitis obliterans (Buerger's disease) Stem cell therapy for treatment of thromboangiitis obliterans (Buerger's disease) (2018) · Cochrane | no estimate extracted | NR | No studies |
Subcutaneous unfractionated heparin vs low molecular weight heparin Asymptomatic VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism (2017) · Cochrane | no estimate extracted | NR | No studies |
Subcutaneous unfractionated heparin vs intravenous unfractionated heparin Asymptomatic VTE at 3 months · people aged ≥ 18 years with a diagnosis of new or recurrent VTE Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism (2017) · Cochrane | no estimate extracted | NR | No studies |
Metoprolol vs placebo AAA‐related death, 6 months4 · patients of any age with AAA less than 30 mm in diameter Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in… (2017) · Cochrane | no estimate extracted | NR | No studies |
VTE extended prophylaxis vs another VTE extended prophylaxis All‐cause mortalitye · patients with unprovoked venous thromboembolism Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in… (2017) · Cochrane | no estimate extracted | NR | No studies |
VTE extended prophylaxis vs another VTE extended prophylaxis Strokeg · patients with unprovoked venous thromboembolism Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in… (2017) · Cochrane | no estimate extracted | NR | No studies |
VTE extended prophylaxis vs another VTE extended prophylaxis Myocardial infarction · patients with unprovoked venous thromboembolism Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in… (2017) · Cochrane | no estimate extracted | NR | No studies |
VTE extended prophylaxis vs another VTE extended prophylaxis VTE‐related mortalitya · patients with unprovoked venous thromboembolism Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Idrabiotaparinux vs idraparinux Heparin‐induced thrombocytopenia ‐ not reported · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Low molecular weight heparin and idraparinux vs standard therapy Major bleeding during the initial treatment · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Low molecular weight heparin and idraparinux vs standard therapy All‐cause mortality · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Low molecular weight heparin and idraparinux vs standard therapy Heparin‐induced thrombocytopenia · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Low molecular weight heparin and idraparinux vs standard therapy All harmful effects · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Idraparinux vs standard therapy Major bleeding during the initial treatment · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Idraparinux vs standard therapy Heparin‐induced thrombocytopenia · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Fondaparinux plus vitamin K antagonist vs standard therapy Heparin‐induced thrombocytopenia ‐ not measured · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Idrabiotaparinux vs idraparinux Major bleeding during the initial treatment ‐ not reported · people > 18 years of age with a diagnosed deep vein thrombosis Pentasaccharides for the treatment of deep vein thrombosis (2017) · Cochrane | no estimate extracted | NR | No studies |
Hand‐assisted laparoscopic repair vs EVAR Long‐term complications (12 months or longer if reported) · People undergoing elective abdominal aortic aneurysm repair Laparoscopic surgery for elective abdominal aortic aneurysm repair (2017) · Cochrane | no estimate extracted | NR | No studies |
Hand‐assisted laparoscopic repair vs EVAR All‐cause mortality/survival (> 30 days) · People undergoing elective abdominal aortic aneurysm repair Laparoscopic surgery for elective abdominal aortic aneurysm repair (2017) · Cochrane | no estimate extracted | NR | No studies |
Hand‐assisted laparoscopic repair vs EVAR Length of ICU stay (days) · People undergoing elective abdominal aortic aneurysm repair Laparoscopic surgery for elective abdominal aortic aneurysm repair (2017) · Cochrane | no estimate extracted | NR | No studies |
Vitamin K antagonists vs placebo Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee… (2016) · Cochrane | no estimate extracted | NR | No studies |
Vitamin K antagonists vs placebo Minor bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee… (2016) · Cochrane | no estimate extracted | NR | No studies |
Anticoagulants (chosen at investigators' discretion) vs placebo Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee… (2016) · Cochrane | no estimate extracted | NR | No studies |
Anticoagulants (chosen at investigators' discretion) vs placebo Minor bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee… (2016) · Cochrane | no estimate extracted | NR | No studies |
Vitamin K antagonists vs heparin Bleeding ‐ clinically indicated non‐major Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee… (2016) · Cochrane | no estimate extracted | NR | No studies |
Heparin vs placebo Clinically relevant non‐major bleeding Treatment duration 28 ‐ 42 days · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee… (2016) · Cochrane | no estimate extracted | NR | No studies |